Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GNAS antisense RNA 1 (GNAS-AS1) is a long non-coding RNA (lncRNA) transcribed from the GNAS gene locus on chromosome 20q13.3. It is a paternally-imprinted and antisense transcript to the GNAS gene, which encodes the alpha subunit of the stimulatory G protein. GNAS-AS1 influences the expression of the GNAS complex locus, is involved in the regulation of multiple cellular functions including cell proliferation, apoptosis, and epithelial-mesenchymal transition, and is implicated in the development of a variety of diseases such as cancer (breast, lung, and pituitary), pseudohypoparathyroidism type Ib, McCune-Albright syndrome, and metabolic disorders. GNAS-AS1 exerts its effects primarily through interactions with microRNAs (such as miR-433-3p) and other gene regulatory mechanisms. It is not a classical drug target such as a receptor, enzyme, or transporter, but has significance as a biomarker and regulator of disease pathogenesis.
Not a direct drug target; functions by regulating microRNAs (e.g., miR-433-3p), gene expression, and signaling axes such as miR-433-3p/GATA3 and miR-433-3p/Rab3A
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GNAS antisense RNA 1 (GNAS-AS1).